Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin

We have previously reported the use of one-bead-one-compound (OBOC) combinatorial technology to develop a disulfide cyclic, Arg-Gly-Asp–containing octapeptide LXW7 (cGRGDdvc), that targets αvβ3 integrin with high affinity and specificity. αvβ3 integrin is known to be overexpressed in many cancers and in tumor vasculature, and it has been established as a cancer therapeutic target. To further optimize LXW7, we have performed systematic structure–activity relationship studies. On the basis of the results, two highly focused OBOC peptide libraries were designed, synthesized, and screened against αvβ3 integrin–transfected K562 cells. One of the best ligands, LXW64, was found to have 6.6-fold higher binding affinity than LXW7, and showed preferential binding to cells expressing αvβ3 integrin. In addition to binding strongly to U-87MG glioblastoma cells in vitro, LXW64 also targets U-87MG xenografts implanted in nude mice, indicating that it is an excellent vehicle for the delivery of cytotoxic payload to tumors and tumor blood vessels that overexpress αvβ3 integrin. Mol Cancer Ther; 15(2); 232–40. ©2015 AACR.

[1]  K. Lam,et al.  Development and Applications of Topologically Segregated Bilayer Beads in One-bead One-compound Combinatorial Libraries , 2005 .

[2]  M. Humphries,et al.  Integrin structure. , 2000, Biochemical Society transactions.

[3]  T. Springer,et al.  Integrin structures and conformational signaling. , 2006, Current opinion in cell biology.

[4]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[5]  Kairbaan Hodivala-Dilke,et al.  alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. , 2008, Current opinion in cell biology.

[6]  H. Kessler,et al.  Radiolabelled RGD peptides for imaging and therapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  T. Govender,et al.  An Improved Synthesis of Fmoc-N-methyl-α-amino Acids , 2005 .

[8]  Erkki Ruoslahti,et al.  Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.

[9]  C. Decristoforo,et al.  Radiolabelled RGD peptides and peptidomimetics for tumour targeting. , 2009, Frontiers in bioscience.

[10]  M. Wilchek,et al.  Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. , 1990, European journal of biochemistry.

[11]  V. Ambrosini,et al.  Radiopeptide Imaging and Therapy in Europe , 2011, The Journal of Nuclear Medicine.

[12]  K. Lam,et al.  Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. , 2009, Journal of medicinal chemistry.

[13]  G. Tucker.  Integrins: Molecular targets in cancer therapy , 2006, Current oncology reports.

[14]  J. Richardson,et al.  The anatomy and taxonomy of protein structure. , 1981, Advances in protein chemistry.

[15]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[16]  Fan Wang,et al.  Integrin αvβ3‐targeted cancer therapy , 2008 .

[17]  Xiaoyuan Chen,et al.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy. , 2008, Drug development research.

[18]  Kit S Lam,et al.  Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. , 2006, Nature chemical biology.

[19]  M. Ohba,et al.  Effect of cyclic RGD peptide on cell adhesion and tumor metastasis. , 1991, Biochemical and biophysical research communications.

[20]  J. Taylor,et al.  Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. , 2001, Journal of medicinal chemistry.

[21]  Kit S Lam,et al.  Therapeutic cancer targeting peptides. , 2002, Biopolymers.

[22]  S. Alahari,et al.  Important role of integrins in the cancer biology , 2010, Cancer and Metastasis Reviews.

[23]  M. Graham,et al.  Radiopeptide Imaging and Therapy in the United States , 2011, The Journal of Nuclear Medicine.

[24]  S. Schuldiner,et al.  Identification of a Glycine Motif Required for Packing in EmrE, a Multidrug Transporter from Escherichia coli* , 2008, Journal of Biological Chemistry.

[25]  Felice C Lightstone,et al.  The Use of One-Bead One-Compound Combinatorial Library Technology to Discover High-Affinity αvβ3 Integrin and Cancer Targeting Arginine-Glycine-Aspartic Acid Ligands with a Built-in Handle , 2010, Molecular Cancer Therapeutics.

[26]  Kit S. Lam,et al.  The "One-Bead-One-Compound" Combinatorial Library Method. , 1997, Chemical reviews.

[27]  K. Lam,et al.  Identifying peptide ligands for cell surface receptors using cell-growth-on-bead assay and one-bead one-compound combinatorial library , 2002, Biotechnology Letters.

[28]  M. Arnaout,et al.  Integrin structure, allostery, and bidirectional signaling. , 2005, Annual review of cell and developmental biology.

[29]  M. Wilchek,et al.  Renal accumulation of streptavidin: potential use for targeted therapy to the kidney. , 1995, Kidney international.

[30]  H. Kessler,et al.  N‐Methylation of Peptides: A New Perspective in Medicinal Chemistry , 2009 .

[31]  Kit S. Lam,et al.  A new type of synthetic peptide library for identifying ligand-binding activity , 1992, Nature.

[32]  Curzio Rüegg,et al.  Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[33]  C. Czaplewski,et al.  Implication of the disulfide bridge in trypsin inhibitor SFTI-1 in its interaction with serine proteinases. , 2010, Bioorganic & medicinal chemistry.

[34]  D. Reardon,et al.  Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. , 2011, Genes & cancer.

[35]  E. Novellino,et al.  A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. , 2002, Journal of medicinal chemistry.